Sort by
Refine Your Search
-
Listed
-
Employer
- Delft University of Technology (TU Delft)
- University of Amsterdam (UvA)
- Delft University of Technology (TU Delft); yesterday published
- Eindhoven University of Technology (TU/e)
- University of Amsterdam (UvA); yesterday published
- Utrecht University
- Wageningen University & Research
- Amsterdam UMC
- Amsterdam UMC; Amsterdam
- Amsterdam UMC; 27 Sep ’25 published
- Amsterdam UMC; Published today
- Amsterdam UMC; Published yesterday
- Amsterdam UMC; today published
- Delft University of Technology (TU Delft); Delft
- Delft University of Technology (TU Delft); 26 Sep ’25 published
- Delft University of Technology (TU Delft); Published 21 Nov ’25
- Eindhoven University of Technology (TU/e); Eindhoven
- Eindhoven University of Technology (TU/e); yesterday published
- Erasmus MC (University Medical Center Rotterdam)
- Erasmus MC (University Medical Center Rotterdam); today published
- European Space Agency
- Leiden University Medical Center (LUMC)
- Maastricht University (UM)
- Maastricht University (UM); yesterday published
- Radboud University
- Radboud University Medical Center (Radboudumc)
- University Medical Center Utrecht (UMC Utrecht); today published
- University of Amsterdam (UvA); 26 Sep ’25 published
- University of Amsterdam (UvA); Published today
- University of Amsterdam (UvA); Published yesterday
- University of Twente
- University of Twente (UT)
- University of Twente (UT); Published today
- University of Twente (UT); today published
- Wageningen University and Research Center
- 25 more »
- « less
-
Field
-
targets will then be investigated in obese animal models to dissect the underlying cellular mechanisms and test potential compounds that modulate microglial pathways, with the ultimate goal of developing
-
-subject clinical and pathological information with morphological and molecular knowledge of induced pluripotent stem cells (iPSC) of PD(D)/DLB patients to identify molecular profiles and drug targets. We
-
) multi-omics analysis for the identification of therapeutic targets (biomarkers or druggable targets). The candidate will also develop and implement AI-driven tools to predict disease prognosis and
-
increasing cited as a key requirement to meet net-zero emission goals in 2050 and temperature targets for 2100. Yet, CDR activities span a range of technological and biological systems, including afforestation
-
With the advent of novel immunotherapies such as conventional antibodies, T cell–targeting antibodies, antibody–drug conjugates and CAR T cells, the treatment of multiple myeloma is advancing
-
recent afforestation in many temperate regions. Your job The legacy of LULCC decisions today will impact the remaining carbon budget required to achieve climate targets in the coming decades
-
risk—paving the way for better-targeted prevention strategies. We have obtained funding for a 2-year full time post-doc position, starting date between February 2 (earliest) and May 4 (latest) 2026
-
operationalizing next-generation LLM solutions that enable ING to streamline core processes, strengthen compliance, and scale agent-based AI systems. The position potentially targets at one of the following three
-
that enable ING to streamline core processes, strengthen compliance, and scale agent-based AI systems. The position potentially targets at one of the following three high-impact research streams: Quality
-
cells and their tumor targets. To further advance the impact of these tools in the biological and clinical setting, this project will focus on increasing sensitivity of existing technologies to enable